Immune Checkpoint Inhibitors in pMMR Metastatic Colorectal Cancer: A Tough Challenge.

ABSTRACT: The introduction of checkpoint inhibitors provided remarkable achievements in several solid tumors but only 5% of metastatic colorectal cancer (mCRC) patients, i.e., those with bearing microsatellite instable (MSI-high)/deficient DNA mismatch repair (dMMR) tumors, benefit from this approach. The favorable effect of immunotherapy in these patients has been postulated to be due to an increase in neoantigens due to their higher somatic mutational load, also associated with an abundant infiltration of immune cells in tumor microenvironment (TME). While in patients with dMMR tumors checkpoint inhibitors allow achieving durable response with dramatic survival improvement, current results in patients with microsatellite stable (MSS or MSI-low)/proficient DNA mismatch repair (pMMR) tumors are disa

SUBMITTER: Marmorino F 

PROVIDER: S-EPMC7465130 | biostudies-literature | 2020 Aug

REPOSITORIES: biostudies-literature